NCT03122340

Polyprenols (Ropren) in Acute Coronary Syndrome

Single-center Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Polyprenols (ROPREN) in Subjects With Acute Coronary Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to determine efficacy and safety of polyprenols (ROPREN) using in patients with acute coronary syndrome

Detailed description

This study is randomized double blind placebo controlled. Patients with acute coronary syndrome taking standard therapy including atorvastatin 40 mg/day were randomized into 2 groups: group 1 takes Ropren 8 drops 3 times per day for 3 week, then 5 drops 3 times per day for 5 weeks; group 2 take placebo in the same dose regimen. The hepatoprotective, hypolipidemic, antiinflammatory, cognitive, antidepression functions evaluates after one and two - month therapy

Conditions

• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	Ropren	Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
OTHER	Oil	Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks

Timeline

• Start date: 2015-11-01
• Primary completion: 2017-12-31
• Completion: 2018-02-28
• First posted: 2017-04-20
• Last updated: 2018-04-26

Locations

1 site across 1 country: Russia